Previous 10 | Next 10 |
Viscient will turn its attention to 3D bioprinting lung tissue for infectivity research to assist global efforts to combat SARS-CoV-2, the novel coronavirus that causes COVID-19 Organovo failed to receive a majority of stockholder votes in favor of its merger, and 47 million shares...
Organovo Holdings, Inc. (“Organovo”) (Nasdaq: ONVO) convened, on March 26, 2020, the special meeting of stockholders and then adjourned the special meeting of stockholders until Tuesday, April 7, 2020 10:00 A.M. Pacific Time at www.virtualshareholdermeeting.com/ONVO2020 to s...
Intends to Vote "AGAINST" Proposed Merger With Tarveda Intends to vote “FOR” Reverse Stock Split and Against All Other Provisions Believes the Board, Which Has Presided Over Significant Value Destruction in Recent Years, Has Asked Stockholders to Take an U...
Intends to Vote "AGAINST" Proposed Merger With Tarveda Believes the Board Has a Track Record of Bad Decisions and Poor Business Judgment Since Mid-2017, Including Hiring a CEO Who Failed Stockholders Reminds Stockholders That the Board Retained a Failing CE...
Recommends Stockholders Vote "FOR" Proposed Merger with Tarveda Organovo Holdings, Inc. (“Organovo”) (NASDAQ: ONVO) today announced that it has filed definitive proxy materials with the U.S. Securities and Exchange Commission and has mailed these materials and a letter to...
Organovo chose to shut down rather than find a way forward itself with bioprinting Organovo is proposing a reverse merger with Tarveda, a non-strategic option that is a complete investor mismatch; Tarveda, which is in the cancer-drug space, would not use the Organovo bioprinting intell...
Keith Murphy, founder, former CEO and Chairman Emeritus of Organovo, says bioprinting and similar technologies are going strong and still growing Companies in the space are finding support from institutional capital sources, and those with tools and service business models are achie...
These Penny Stocks Can Be Bought For Under $1 Right Now; Will That Be The Case After The Holidays? One of the most important things to keep in mind about penny stocks is the fact these stocks generally trade below $5. That allows an investor to buy a large number of shares for a relatively s...
Organovo Holdings (NASDAQ: ONVO ) is up 21% premarket on entering into a merger agreement with Tarveda Therapeutics, a privately-held, clinical stage biopharmaceutical company. More news on: Organovo Holdings, Inc., Healthcare stocks news, Stocks on the move, Read mo...
Combined company to operate as Tarveda Therapeutics upon closing of merger Transaction to advance Tarveda’s proprietary Pentarin® miniature drug conjugates including its two clinical programs for the treatment of solid tumor malignancies Companies to host conference ca...
News, Short Squeeze, Breakout and More Instantly...
Organovo Holdings Inc. Company Name:
ONVO Stock Symbol:
NASDAQ Market:
Organovo Holdings Inc. Website:
A look at the top 10 most actives in the United States Conduit Pharmaceuticals Inc. (CDT) rose 40.0% to $0.3361 on volume of 63,970,490 shares Yoshitsu Co. Ltd (TKLF) rose 64.0% to $0.5024 on volume of 62,618,792 shares Silo Pharma Inc. (SILO) rose 91.8% to $2.0522 on volume of 59,055,593...
SAN DIEGO, July 16, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announced that Executive Chairman Keith Murphy presen...